Seasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025

Market: Pharmaceuticals and Healthcare

Europe, 290 pages report, published by GlobalData

Report ThumbnailNovember-2016
Seasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025

Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

A quadrivalent formulation of Intanza Intradermal is anticipated to be launched in the EU, following the launch of quadrivalent Fluzone Intradermal in the US. The sales of quadrivalent Intanza Intradermal are expected to increase to $1.5m in 2025. Its growth will be driven by its improved immunogenicity in elderly patients compared to typical influenza vaccines and the increase in the size of Germany’s elderly population.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Seasonal Influenza Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2015-2025 in 5EU.
  • 1.2 List of Figures
  • Figure 1: Influenza Virus Structure 17
  • Figure 2: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016 166
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025 167
  • Figure 4: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025 203
  • Figure 5: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025 208
  • Figure 6: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025 213
  • Figure 7: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025 219
  • Figure 8: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025 224
  • 1.1 List of Tables
  • Table 1: Notable Influenza Pandemics 20
  • Table 2: Influenza Symptoms 22
  • Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016 24
  • Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016 26
  • Table 5: Country Profile - France 27
  • Table 6: Country Profile - Germany 32
  • Table 7: Country Profile - Italy 38
  • Table 8: Country Profile - Spain 44
  • Table 9: Country Profile - UK 48
  • Table 10: Leading Seasonal Influenza Vaccines, 2016 54
  • Table 11: Product Profile - Fluzone Quadrivalent 56
  • Table 12: Immunogenicity Profile of Fluzone Quadrivalent 57
  • Table 13: Local and Systemic AEs of Fluzone Quadrivalent 58
  • Table 14: Fluzone Quadrivalent SWOT Analysis, 2016 59
  • Table 15: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025 61
  • Table 16: Product Profile - Fluzone High-Dose 62
  • Table 17: Immunogenicity of Fluzone High-Dose Compared with Fluzone 64
  • Table 18: Local and Systemic AEs of Fluzone High-Dose 65
  • Table 19: Fluzone High-Dose SWOT Analysis, 2016 66
  • Table 20: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025 68
  • Table 21: Product Profile - Fluzone Intradermal 70
  • Table 22: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent 72
  • Table 23: Local andsystemic AEs of Fluzone Intradermal Quadrivalent 73
  • Table 24: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016 74
  • Table 25: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025 76
  • Table 26: Product Profile - Vaxigrip 78
  • Table 27: Cumulative Incidence of Influenza Infection in Children 79
  • Table 28: Local and Systemic AEs of Vaxigrip 80
  • Table 29: Vaxigrip SWOT Analysis, 2016 80
  • Table 30: Global Sales Forecast ($m) for Vaxigrip, 2015-2025 82
  • Table 31: Product Profile - Fluarix Tetra 84
  • Table 32: Immunogenicity Profile of Fluarix Tetra 85
  • Table 33: Local and Systemic AEs of Fluarix Tetra 86
  • Table 34: Fluarix Tetra SWOT Analysis, 2016 87
  • Table 35: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025 89
  • Table 36: Product Profile - Fluvirin 90
  • Table 37: Immunogenicity of Fluvirin in Adults 91
  • Table 38: Local and Systemic AEs of Fluvirin 92
  • Table 39: Fluvirin SWOT Analysis, 2016 93
  • Table 40: Global Sales Forecast ($m) for Fluvirin, 2015-2025 94
  • Table 41: Product Profile - Afluria 95
  • Table 42: Immunogenicity of Afluria in Adults 96
  • Table 43: Local and Systemic AEs of Afluria 97
  • Table 44: Afluria SWOT Analysis, 2016 98
  • Table 45: Global Sales Forecast ($m) for Afluria, 2015-2025 99
  • Table 46: Product Profile - Agrippal 101
  • Table 47: Immunogenicity of Agrippal 102
  • Table 48: Local and Systemic AEs of Agrippal 102
  • Table 49: Agrippal SWOT Analysis, 2016 103
  • Table 50: Global Sales Forecast ($m) for Agrippal, 2015-2025 104
  • Table 51: Product Profile - Fluad 106
  • Table 52: Immunogenicity Comparison of Fluad Versus Agriflu 107
  • Table 53: Local and Systemic AEs of Fluad 108
  • Table 54: Fluad SWOT Analysis, 2016 109
  • Table 55: Global Sales Forecast ($m) for Fluad, 2015-2025 111
  • Table 56: Product Profile - FluMist Quadrivalent 113
  • Table 57: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent 115
  • Table 58: AEs of FluMist Quadrivalent 116
  • Table 59: FluMist Quadrivalent SWOT Analysis, 2016 116
  • Table 60: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025 118
  • Table 61: Product Profile - Flublok 120
  • Table 62: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose 122
  • Table 63: Local and Systemic AEs of Flublok 123
  • Table 64: Flublok SWOT Analysis, 2016 124
  • Table 65: Global Sales Forecast ($m) for Flublok, 2015-2025 126
  • Table 66: Product Profile - Flucelvax 128
  • Table 67: Immunogenicity of Flucelvax 129
  • Table 68: Local and Systemic AEs of Flucelvax 130
  • Table 69:Flucelvax SWOT Analysis, 2016 131
  • Table 70: Global Sales Forecast ($m) for Flucelvax, 2015-2025 133
  • Table 71: Summary of Other Marketed Seasonal Influenza Vaccines, 2016 135
  • Table 72: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016 139
  • Table 73: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016 166
  • Table 74: Quadrivalent Versions of Marketed Vaccines 169
  • Table 75: Product Profile - Seasonal Influenza VLP Vaccine 172
  • Table 76: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 177
  • Table 77: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025 179
  • Table 78: Product Profile - VN-100 181
  • Table 79: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine 182
  • Table 80: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine 183
  • Table 81: VN-100 SWOT Analysis, 2016 186
  • Table 82: Global Sales Forecast ($m) for VN-100, 2015-2025 187
  • Table 83: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine 189
  • Table 84: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016 193
  • Table 85: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025 195
  • Table 86: Promising Vaccines in Early-Stage Development, 2016 196
  • Table 87: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016 199
  • Table 88: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025 202
  • Table 89: Key Events Impacting Sales for Seasonal Influenza in France, 2015‒2025 204
  • Table 90: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 204
  • Table 91: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025 207
  • Table 92: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015‒2025 209
  • Table 93: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 209
  • Table 94: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025 212
  • Table 95: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015‒2025 214
  • Table 96: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 215
  • Table 97: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025 218
  • Table 98: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015‒2025 220
  • Table 99: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 220
  • Table 100: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025 223
  • Table 101: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015‒2025 225
  • Table 102: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015‒2025 226
  • Table 103: Key Launch Dates 271
  • Table 104: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 285
  • 1 Table of Contents
  • 1 Table of Contents 2
  • 1.1 List of Tables 7
  • 1.2 List of Figures 12
  • 2 Introduction 13
  • 2.1 Catalyst 13
  • 2.2 Related Reports 14
  • 2.3 Upcoming Related Reports 14
  • 3 Disease Overview 15
  • 3.1 Etiology and Pathophysiology 15
  • 3.1.1 Etiology 15
  • 3.1.2 Pathophysiology 20
  • 3.1.3 Symptoms and Prognosis 21
  • 4 Disease Management 23
  • 4.1 Seasonal Influenza Immunization Policy 23
  • 4.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines 24
  • 4.2 France 26
  • 4.2.1 Influenza Immunization Recommendations and Policies 28
  • 4.2.2 Clinical Practice 29
  • 4.3 Germany 31
  • 4.3.1 Influenza Immunization Recommendations and Policies 32
  • 4.3.2 Clinical Practice 34
  • 4.4 Italy 36
  • 4.4.1 Influenza Immunization Recommendations and Policies 38
  • 4.4.2 Clinical Practice 40
  • 4.5 Spain 42
  • 4.5.1 Influenza Immunization Recommendations and Policies 44
  • 4.5.2 Clinical Practice 46
  • 4.6 UK 47
  • 4.6.1 Influenza Immunization Recommendations and Policies 49
  • 4.6.2 Clinical Practice 51
  • 5 Competitive Assessment 53
  • 5.1 Overview 53
  • 5.2 Product Profiles - Major Brands, Inactivated Vaccines 55
  • 5.2.1 Fluzone Quadrivalent 55
  • 5.2.2 Fluzone High-Dose 61
  • 5.2.3 Fluzone Intradermal 68
  • 5.2.4 Vaxigrip 76
  • 5.2.5 Fluarix Tetra 82
  • 5.2.6 Fluvirin 89
  • 5.2.7 Afluria 94
  • 5.2.8 Agrippal 100
  • 5.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted) 104
  • 5.3.1 Fluad 104
  • 5.4 Product Profiles - Major Brands, Live-Attenuated Vaccines 111
  • 5.4.1 FluMist Quadrivalent 111
  • 5.5 Product Profiles - Major Brands, Cell Cultured Vaccines 119
  • 5.5.1 Flublok 119
  • 5.5.2 Flucelvax 126
  • 5.6 Other Seasonal Influenza Vaccines 133
  • 5.6.1 Influvac 133
  • 5.6.2 Minor Brands 135
  • 6 Unmet Needs and Opportunity Analysis 136
  • 6.1 Overview 136
  • 6.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines 140
  • 6.2.1 Unmet Need 140
  • 6.2.2 Gap Analysis 141
  • 6.2.3 Opportunity 144
  • 6.3 Immunization Policies Targeting Children and Adolescents 145
  • 6.3.1 Unmet Need 145
  • 6.3.2 Gap Analysis 146
  • 6.3.3 Opportunity 146
  • 6.4 Enhanced Vaccine Efficacy in High-Risk Groups 148
  • 6.4.1 Unmet Need 148
  • 6.4.2 Gap Analysis 149
  • 6.4.3 Opportunity 151
  • 6.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies 152
  • 6.5.1 Unmet Need 152
  • 6.5.2 Gap Analysis 153
  • 6.5.3 Opportunity 154
  • 6.6 Improving the Cost-Effectiveness of Influenza Vaccines 155
  • 6.6.1 Unmet Need 155
  • 6.6.2 Gap Analysis 156
  • 6.6.3 Opportunity 157
  • 6.7 Vaccines with Broader Influenza Strain Coverage 158
  • 6.7.1 Unmet Need 158
  • 6.7.2 Gap Analysis 159
  • 6.7.3 Opportunity 160
  • 6.8 Improved Vaccine Safety Profile 161
  • 6.8.1 Unmet Need 161
  • 6.8.2 Gap Analysis 162
  • 6.8.3 Opportunity 163
  • 7 Pipeline Assessment 164
  • 7.1 Overview 164
  • 7.2 Promising Vaccines in Clinical Development 165
  • 7.2.1 Seasonal Influenza VLP Vaccine 170
  • 7.2.2 VN-100 179
  • 7.2.3 Quadrivalent Seasonal Influenza VLP Vaccine 187
  • 7.3 Promising Vaccines in Early-Stage Development 195
  • 7.3.1 FLU-v 196
  • 7.3.2 M-001 197
  • 7.3.3 TAK-850 198
  • 7.3.4 VAX-2012Q 198
  • 7.4 Other Vaccines in Development Outside the 7MM 199
  • 8 Market Outlook 200
  • 8.1 France 200
  • 8.1.1 Forecast 200
  • 8.1.2 Key Events 204
  • 8.1.3 Drivers and Barriers 204
  • 8.2 Germany 205
  • 8.2.1 Forecast 205
  • 8.2.2 Key Events 209
  • 8.2.3 Drivers and Barriers 209
  • 8.3 Italy 210
  • 8.3.1 Forecast 210
  • 8.3.2 Key Events 214
  • 8.3.3 Drivers and Barriers 215
  • 8.4 Spain 216
  • 8.4.1 Forecast 216
  • 8.4.2 Key Events 220
  • 8.4.3 Drivers and Barriers 220
  • 8.5 United Kingdom 221
  • 8.5.1 Forecast 221
  • 8.5.2 Key Events 225
  • 8.5.3 Drivers and Barriers 226
  • 9 Appendix 227
  • 9.1 Bibliography 227
  • 9.2 Abbreviations 265
  • 9.3 Methodology 269
  • 9.4 Forecasting Methodology 269
  • 9.4.1 Vaccine Coverage 269
  • 9.4.2 Vaccines Included 270
  • 9.4.3 Key Launch Dates 270
  • 9.4.4 Influenza Vaccine Tender System Assumptions 271
  • 9.4.5 General Pricing Assumptions 272
  • 9.4.6 Individual Vaccine Assumptions 273
  • 9.4.7 Pricing of Pipeline Agents 281
  • 9.5 Primary Research - KOLs Interviewed for this Report 282
  • 9.6 Primary Research - Prescriber Survey 285
  • 9.7 About the Authors 286
  • 9.7.1 Analyst 286
  • 9.7.2 Therapy Area Director 286
  • 9.7.3 Epidemiologists 287
  • 9.7.4 Director of Epidemiology 288
  • 9.7.5 Global Director of Therapy Analysis and Epidemiology 288
  • 9.8 About GlobalData 289
  • 9.9 Disclaimer 289

Please select a license type

Share

Related Products

GlobalDataSeasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025Product ThumbnailSeasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025, Industry Report available for $6995Product #: 631547
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved